CNBC
20 Feb 2026, 16:57 UTC · 29w ago
Verdict
Headline leans bullish. We score KO −0.50.
Score contradicts the headline.
Leans bullish
From its wording — no explicit rating
−0.50strongly bearish
Which stocks this story touches
Continue reading
5 related stories
More negative than 79% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 79% of ticker scores this week
Will continue to face higher costs due to 50% aluminum tariffs.
More negative than 79% of ticker scores this week
Will continue to face higher costs due to 50% aluminum tariffs.
More negative than 76% of ticker scores this week
Expects between $3 billion and $4 billion in tariff costs this year.
More negative than 69% of ticker scores this week
Expects a net tariff impact of roughly $2 billion in 2026.
More positive than 53% of ticker scores this week
Inked a deal for a three-year exemption from pharma tariffs in exchange for U.S. investment.
More positive than 53% of ticker scores this week
Inked a deal for a three-year exemption from pharma tariffs in exchange for U.S. investment.
More positive than 53% of ticker scores this week
Inked a deal for a three-year exemption from pharma tariffs in exchange for U.S. investment.
More positive than 76% of relationship scores this week
[mutual] Both are identified as major U.S. automakers facing tariff costs.
More positive than 56% of relationship scores this week
[mutual] Both companies are mentioned as facing higher costs due to aluminum tariffs on their product manufacturing.
More positive than 56% of relationship scores this week
[mutual] Both companies are mentioned as facing higher costs due to aluminum tariffs on their product manufacturing.
More positive than 56% of relationship scores this week
[mutual] Both companies are mentioned as facing higher costs due to aluminum tariffs on their product manufacturing.
More positive than 35% of relationship scores this week
[mutual] Both are major pharmaceutical players that entered a joint agreement with the administration regarding drug pricing and tariffs.
More positive than 35% of relationship scores this week
[mutual] Both are major pharmaceutical players that entered a joint agreement with the administration regarding drug pricing and tariffs.
More positive than 35% of relationship scores this week
[mutual] Both are major pharmaceutical players that entered a joint agreement with the administration regarding drug pricing and tariffs.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
2d ago
+12.0%
Price is moving against the score
$88.36 vs $78.91 close before publication (Feb 19) · not market-adjusted
KO chart →
